Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Adjusted selling and marketing

Similar metrics at other companies

Rimini Street, Inc. logo
RMNIReportable Segment — Selling And Marketing Expense, Adjusted
$37.79M+13.4%
Paylocity logo
PCTYReportable Segment — Selling and Marketing Expense, Adjusted
$97.35M+5.0%
Calix logo
CALXReportable Segment — Selling And Marketing Operating Expense, Adjusted
$56.71M+7.8%
Elanco Animal Health Inc. logo
ELANReportable Segment — Marketing and selling
$310M+14.0%
Logitech International logo
LOGIReportable Segment — Marketing and selling
$207.92M+14.3%
Open Text logo
OTEXReportable Segment — Adjusted marketing
$50.36M-1.1%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$997.34M-11.9%
Enterprise value$1.26B+6.9%
P/E194.1×
P/S1.4×-0.2×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept pcrx:SellingAndMarketingAdjusted.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Less:
Adjusted cost of goods sold (1)34,77032,590
Adjusted research and development (1)25,36223,101
Adjusted selling and marketing (1)58,16655,571
Adjusted general and administrative (1)25,71220,609
Stock-based compensation (1)13,53914,553
Amortization of acquired intangible assets14,32214,322
Changes in the fair value of contingent consideration(2,277)(2,675)

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — adjusted selling and marketing?
Pacira BioSciences, Inc. (PCRX) reported business segments — adjusted selling and marketing of $58.17M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — adjusted selling and marketing changed year-over-year?
Pacira BioSciences, Inc.'s business segments — adjusted selling and marketing increased by 4.7% year-over-year, from $55.57M to $58.17M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — adjusted selling and marketing?
Over 3 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — adjusted selling and marketing has grown at a 16.0% compound annual growth rate (CAGR), from $145M to $226.62M.
What does business segments — adjusted selling and marketing mean?
Includes the adjusted costs associated with promoting, selling, and distributing the segment's products, excluding non-recurring items. It measures the investment intensity required to maintain or grow market share and brand awareness for the segment.

Ask your AI about Pacira BioSciences, Inc.'s business segments — adjusted selling and marketing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude